title: Clinical relevance of growth factor antagonists in the treatment of benign prostatic hyperplasia.
abstract: Changing demography and expectations about maintaining quality of life mean that an increasing number of men will require treatment for benign prostatic hyperplasia (BPH). Many growth factors have a role in the development of BPH. Consequently growth factor antagonists offer an attractive therapeutic option. In double-blind randomised trials Tadenan, a drug known to have growth factor antagonist activity, conferred significant improvement of urinary symptoms, maximum flow rate and residual volume, with no serious side-effects. Therapeutic outcome could be enhanced in a number of ways including matching patients with particular cell type overgrowth for treatment with a growth factor antagonist specific for that cell type. Full exploitation of this approach awaits the development of less invasive means of determining the cell type affected.
authors.affiliation: Department of Urology, Hôpital Saint-Louis, Paris, France.
authors.forename: F
authors.initials: F
authors.lastname: Desgrandchamps
mesh_terms: D005233:Fatty Alcohols / Q000627:therapeutic use; D006131:Growth Inhibitors / Q000627:therapeutic use*; D006133:Growth Substances / Q000502:physiology; D006801:Humans; D008297:Male; D010936:Plant Extracts / Q000627:therapeutic use; D011470:Prostatic Hyperplasia / Q000188:drug therapy* / Q000209:etiology
chemical_list: D005233:Fatty Alcohols; D006131:Growth Inhibitors; D006133:Growth Substances; D010936:Plant Extracts; C009375:Tadenan